Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis.

Purpose: The aim of this study was to describe the efficacy and safety of anti–interleukin 6 receptor antibody (tocilizumab [TCZ]) in patients with severe or refractory Takayasu arteritis (TA). Methods: We describe 8 Colombian patients with severe and/or refractory TA treated with TCZ during a period of at least 9 months. Clinical, radiological, biological, and associated treatments were evaluated before, during, and after TCZ infusions. Results: The median age at evaluation was 31 years (12–43 years). All patients were female and experienced clinical and biological improvement, in addition to a corticosteroid-sparing effect from a median dose of 50 mg/d at baseline (30–60 mg/d) to 6.25 mg/d (2.5–10 mg/d) at 9 months. In 4 cases, in which imaging studies were available, an improvement was observed.

• Autores: Cañas Dávila, Carlos Alberto
• Tipo de recurso: Article of investigation
• Fecha de publicación: 2014
• Institución: Universidad ICESI
• Repositorio: Repositorio ICESI
• Idioma: eng
• OAI Identifier: oai:repository.icesi.edu.co:10906/78520
• Acceso en línea: http://journals.lww.com/jclinrheum/Abstract/2014/04000/Efficacy_and_Safety_of_Anti_Interleukin_6_Receptor.2.aspx; http://hdl.handle.net/10906/78520; http://dx.doi.org/10.1097/RHU.0000000000000098
• Palabra clave: Arteritis de Takayasu; Tratamiento; Ciencias socio biomédicas; Biomedical sciences; Medicina; Interleukin-6; Reumatología
• Rights: openAccess
• License: https://creativecommons.org/licenses/by-nc-nd/4.0/